Although exact terms were not disclosed, 4D Molecular Therapeutics Inc. (4DMT) CEO David Kirn told BioWorld that Roche Holding AG has "significantly increased" its funding commitment, broadening the research from "a small handful of rare retinal disease indications" in 2016 to take in ophthalmology bids that include large-market prospects as well.